Sanofi starts phase 3 EU trial of combined COVID-influenza vaccine
Start here
Sanofi has launched a phase 3 trial in the European Union of its combined COVID/influenza vaccine pairing Nuvaxovid with Fluzone High-Dose. The study, registered as CTIS 2026-526221-18-00, plans to enroll 10,745 participants across 12 countries, with completion expected on February 10, 2028. The product already holds FDA Fast Track designation. Open questions include the trial's efficacy and safety results, which will determine whether the combination reaches market, and whether the pairing of Nuvaxovid with Flublok will eventually advance to its own late-stage testing, as no phase 3 trial for that combination is currently planned.
Written by a model from the reports · updated 2 hours ago
Coverage timeline
Follow the coverage to see the different angles.
- reddit.comPickSanofi has launched a phase 3 trial in the EU for one of their combo COVID / Influenza vaccines (Nuvaxovid + FluZone High Dose)
Sanofi has launched a phase 3 trial in the EU of its Nuvaxovid + FluZone High Dose combined COVID/influenza vaccine, planning to enroll 10,745 participants across 12 countries. The trial is registered as CTIS 2026-526221-18-00, the product has FDA Fast Track designation, and completion is expected on February 10, 2028. No phase 3 trial is planned yet for the Nuvaxovid + Flublok combination.
Heat trend for this story
Heat now 4·Peak in the comparable set 10 (Oct 22 11:00)·Change over 24h in the comparable set -50%·Participants now 1
Participants counted above, heat below. The trend compares only the participants observed in full throughout, so its set can be smaller than the heat figure itself. Move the pointer or click the chart for an hour's reading; the left and right arrow keys work too.